BACKGROUND: Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). We evaluated the usefulness of plasma proGRP level as a tumor marker for diagnosis and treatment monitoring in patients with SCLC. METHODS: Plasma samples were collected prospectively from 452 [212 non-small cell lung cancer (NSCLC), 105 SCLC, and 135 other diseases] patients who visited the hospital for tissue diagnosis. Plasma proGRP levels were measured using a two-step automated immunoassay. RESULTS: The median proGRP level was significantly higher in patients with SCLC (892.7 pg/mL) than those with NSCLC (32.6 pg/mL, P<0.001) and other diseases (26.6 pg/mL, P<0.001). At cutoff level of 63 pg/mL, proGRP shows 85.7% sensitivity, 90.2% specificity, 72.5% positive predictive value and 95.4% negative predictive value in patients with SCLC. The area under the curve values were 0.93 for distinguishing SCLC from NSCLC, and 0.943 for distinguishing SCLC from the other conditions. Median proGRP level was higher in extensive disease (1,055.2 pg/mL) than limited disease (253.8 pg/mL, P=0.005). Median OS was significantly shorter in patients with extensive disease (6.0±0.7 months) than limited disease (12.7±4.5 months, P<0.01). Among the 39 patients with SCLC who were followed, the median proGRP levels of the 23 responders decreased after chemotherapy (P<0.001). CONCLUSIONS: Plasma proGRP level could be a useful diagnostic and therapeutic monitoring biomarker for patients with SCLC and the initial level may help with SCLC tumor staging.
BACKGROUND:Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). We evaluated the usefulness of plasma proGRP level as a tumor marker for diagnosis and treatment monitoring in patients with SCLC. METHODS: Plasma samples were collected prospectively from 452 [212 non-small cell lung cancer (NSCLC), 105 SCLC, and 135 other diseases] patients who visited the hospital for tissue diagnosis. Plasma proGRP levels were measured using a two-step automated immunoassay. RESULTS: The median proGRP level was significantly higher in patients with SCLC (892.7 pg/mL) than those with NSCLC (32.6 pg/mL, P<0.001) and other diseases (26.6 pg/mL, P<0.001). At cutoff level of 63 pg/mL, proGRP shows 85.7% sensitivity, 90.2% specificity, 72.5% positive predictive value and 95.4% negative predictive value in patients with SCLC. The area under the curve values were 0.93 for distinguishing SCLC from NSCLC, and 0.943 for distinguishing SCLC from the other conditions. Median proGRP level was higher in extensive disease (1,055.2 pg/mL) than limited disease (253.8 pg/mL, P=0.005). Median OS was significantly shorter in patients with extensive disease (6.0±0.7 months) than limited disease (12.7±4.5 months, P<0.01). Among the 39 patients with SCLC who were followed, the median proGRP levels of the 23 responders decreased after chemotherapy (P<0.001). CONCLUSIONS: Plasma proGRP level could be a useful diagnostic and therapeutic monitoring biomarker for patients with SCLC and the initial level may help with SCLC tumor staging.
Entities:
Keywords:
Progastrin-releasing peptide (proGRP); biomarker; small cell lung cancer (SCLC)
Authors: Catharina M Korse; Stefan Holdenrieder; Xiu-yi Zhi; Xiaotong Zhang; Ling Qiu; Andrea Geistanger; Marcus-Rene Lisy; Birgit Wehnl; Daan van den Broek; José M Escudero; Jens Standop; Mu Hu; Rafael Molina Journal: Clin Chim Acta Date: 2014-09-28 Impact factor: 3.786
Authors: S Niho; Y Nishiwaki; K Goto; H Ohmatsu; T Matsumoto; F Hojo; Y Ohe; R Kakinuma; T Kodama Journal: Lung Cancer Date: 2000-03 Impact factor: 5.705
Authors: N Sunaga; S Tsuchiya; K Minato; S Watanabe; N Fueki; H Hoshino; T Makimoto; S Ishihara; R Saito; M Mori Journal: Oncology Date: 1999 Impact factor: 2.935
Authors: Rafael Molina; Stefan Holdenrieder; Jose Maria Auge; Andreas Schalhorn; Rudolph Hatz; Petra Stieber Journal: Cancer Biomark Date: 2010 Impact factor: 4.388
Authors: Ewa Wójcik; Jan K Kulpa; Beata Sas-Korczyńska; Stanisław Korzeniowski; Jerzy Jakubowicz Journal: Anticancer Res Date: 2008 Sep-Oct Impact factor: 2.480
Authors: M Takada; Y Kusunoki; N Masuda; K Matui; T Yana; S Ushijima; K Iida; K Tamura; T Komiya; I Kawase; N Kikui; H Morino; M Fukuoka Journal: Br J Cancer Date: 1996-05 Impact factor: 7.640
Authors: Markus Glatzer; Achim Rittmeyer; Joachim Müller; Isabelle Opitz; Alexandros Papachristofilou; Ioannis Psallidas; Martin Früh; Diana Born; Paul Martin Putora Journal: Eur Respir J Date: 2017-08-24 Impact factor: 16.671